Global Lung Cancer Therapeutics Market to Reach US$ 70,084.5 Million by 2032, Propelled by Rising Prevalence of Lung Cancer

September 25, 2023 | Healthcare

According to the latest report by IMARC Group, titled “Lung Cancer Therapeutics Market Report by Therapy (Targeted Therapy, Immunotherapy, Radiation Therapy, Chemotherapy), Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2024-2032,” the global lung cancer therapeutics market size reached US$ 30,188.8 Million in 2023. Lung cancer therapeutics refers to the medical treatment options available for managing and treating lung cancer. These treatments aim to eliminate cancer cells, control their growth, and improve patients' quality of life. The therapeutic approaches can be broadly categorized into surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Each treatment type is tailored to the specific stage and type of lung cancer, as well as the overall health of the patient. In recent years, numerous advancements in medical research have led to the development of newer, more effective drugs and techniques that target cancer cells more precisely, offering improved survival rates and reduced side effects.

Global Lung Cancer Therapeutics Market Trends:

The increasing prevalence of lung cancer across the globe due to excessive smoking, high exposure to pollutants, and unhealthy lifestyle choices represents the primary factor driving the market growth. Apart from this, numerous advancements in medical technology and research, including the development of novel therapies such as targeted therapy and immunotherapy that offer more personalized treatment options with fewer side effects, have accelerated the product adoption rate. Additionally, inflating healthcare expenditure and heightening awareness about the availability of advanced treatments are propelling market growth. Moreover, several favorable government initiatives and increasing funding for cancer research encouraging the development and quick approval of innovative lung cancer drugs have catalyzed market growth. Besides this, the expanding geriatric population that is more susceptible to cancer has augmented the demand for lung cancer therapeutics. Furthermore, the rising focus on healthcare amid the coronavirus (COVID-19) pandemic and accelerated telemedicine adoption for cancer care that indirectly promotes the use of advanced therapeutics is contributing to market growth. Looking forward, the market value is projected to reach US$ 70,084.5 Million by 2032, expanding at a CAGR of 9.52% during 2024-2032.

Market Summary:

Based on the therapy, the market has been divided into targeted therapy (bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, osimertinib and others); immunotherapy (durvalumab, nivolumab, atezolizumab and pembrolizumab); radiation therapy (external beam, internal beam and systemic); and chemotherapy. At present, targeted therapy represents the largest segment.
On the basis of the cancer type, the market has been bifurcated into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), wherein non-small cell lung cancer (NSCLC) dominates the market.
The market has been segregated based on the distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others. Amongst these, hospital pharmacies account for the majority of the market share.
Region-wise, the market has been segmented into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Amongst these, North America holds the leading position in the market.
The competitive landscape of the market has also been examined, with some of the key players being AbbVie Inc., Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, and Takeda Pharmaceutical Company Limited.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Million
Scope of the Report	Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: Therapy Cancer Type Distribution Channel Region
Therapies Covered	Targeted Therapy: Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, Osimertinib, Others Immunotherapy: Durvalumab, Nivolumab, Atezolizumab, Pembrolizumab Radiation Therapy: External Beam, Internal Beam, Systemic Chemotherapy
Cancer Types Covered	Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
Distribution Channels Covered	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others
Regions Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	AbbVie Inc., Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Company Limited, etc.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Lung Cancer Therapeutics Market to Reach US$ 70,084.5 Million by 2032, Propelled by Rising Prevalence of Lung Cancer

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.